Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG (NOVN)

132
End-of-day quote. End-of-day quote Swiss Exchange - 04/17
74.7 CHF   +0.47%
1d ago Pfizer considers $100 billion bid for AstraZeneca
3d ago NOVARTIS : Sotax to introduce new equipment in india
4d ago NOVARTIS : Patent Issued for Intraocular Lens Surgical System and Method
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

10/04/2012 | 07:16pm US/Eastern
Recommend:
0

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at marta.falconi@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
Recommend :
0
React to this article
Latest news on NOVARTIS AG
1d ago Pfizer considers $100 billion bid for AstraZeneca
3d ago NOVARTIS : Sotax to introduce new equipment in india
4d ago NOVARTIS : Patent Issued for Intraocular Lens Surgical System and Method
5d ago NOVARTIS : Patent Application Titled "Method for Preventing and Treating Cancer ..
5d ago NOVARTIS : "Solid Oral Formulations and Crystalline Forms of an Inhibitor of Apo..
5d ago NOVARTIS : Investigation Report on China Valsartan Hydrochlorothiazide Market, 2..
5d ago NOVARTIS : Carnegie Mellon presents Ricardo Dolmetsch with Carnegie Prize in Min..
5d ago NOVARTIS : Researchers Submit Patent Application, "RNAi INHIBITION OF CTGF FOR T..
5d ago NOVARTIS : Undercover policeman poses as corporate security manager to convict a..
5d ago NOVARTIS : Takes drl to court in us over cancer drug patent
Advertisement
Chart
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Income Statement Evolution
Novartis AG : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF